Oncology,
Journal Year:
2023,
Volume and Issue:
25(4), P. 255 - 261
Published: Jan. 1, 2023
Summary.
Hormone-dependent
malignant
neoplasms
are
the
most
common
form
of
breast
cancer
(BC)
worldwide.
The
high
heterogeneity
clinical
manifestations
and
response
to
treatment
indicates
need
search
for
prognostic
predictive
markers
predict
aggressiveness
course
hormone-dependent
BC
prescribe
individualized
tactics.
MicroRNAs
short
RNA
molecules
that
play
an
important
role
in
regulating
expression
many
genes.
This
is
due
fact
miRNAs
modulators
growth,
differentiation
metastasis
various
histogenesis,
including
BC.
can
be
used
disease
choose
optimal
tactics,
since
their
levels
determined
not
only
tumor
tissue
but
also
blood
serum.
systematization
generalization
results
our
own
research
data
from
literature
on
possibility
using
miRNA
as
perceptiveness
monitor
process
determine
sensitivity
tumors
neoadjuvant
hormonal
therapy.
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: Sept. 20, 2024
Breast
cancer
(BC)
is
one
of
the
frequent
tumors
that
seriously
endanger
physical
and
mental
well-being
in
women
with
strong
heterogeneity,
its
pathogenesis
involves
multiple
risk
factors.
Depending
on
type
BC,
hormonal
therapy,
targeted
immunotherapy
are
current
systemic
treatment
options
along
conventional
chemotherapy.
Despite
significant
progress
understanding
BC
therapeutic
options,
there
still
a
need
to
identify
new
targets
develop
more
effective
treatments.
According
recent
sequencing
profiling
studies,
non-coding
(nc)
RNAs
genes
deregulated
human
cancers
via
deletion,
amplification,
abnormal
epigenetic,
or
transcriptional
regulation,
similarly,
expression
many
ncRNAs
altered
breast
cell
lines
tissues.
The
ability
single
regulate
downstream
gene
related
pathways
provides
theoretical
basis
for
studying
them
drug
development
delivery.
Therefore,
it
far-reaching
explore
role
tumor
their
potential
as
targets.
Here,
our
review
outlines
two
major
ncRNAs,
long
(lncRNAs)
microRNAs
(miRNAs)
diagnostic
prognostic
biomarkers
well
strategies
cancer.
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: May 17, 2024
ABSTRACT
Background
Endocrine
therapy
resistance
(ETR)
in
breast
cancer
is
achieved
via
multiple
pathways
including
a
decrease
ER,
dysregulation
of
cell
cycle
genes,
and/or
mutations
ER/co-activators/co-repressors.
We
have
reported
earlier
that
high
expression
Jumonji
domaining
containing
protein
6
(JMJD6)
induced
ETR
by
depleting
ER
expression.
In
this
study,
3
cellular
models
representing
distinct
pathways;
Tamoxifen
resistant
(TAMR),
Long-term
Estrogen
deprived
(LTEDI),
JMJD6
overexpressing
(JOE)
cells,
and
parental
MCF7
were
subjected
to
RNA-sequencing,
CNC,
ceRNA
network
analysis.
hypothesised
post-comparison
RNA
regulations
are
common
all
lines,
will
reveal
actionable
markers
targets.
These
be
shared
patients
with
ET-resistant
disease,
independent
the
initiating
event.
Results
170
differentially
expressed
genes
found,
these,
73
maintained
same
directionality
(ETR
cassette
genes).
segregated
TCGA
ER+
tumors
into
two
groups,
one
intermixing
ER-tumors.
Pathway-based
curation
identified
21
(7
up-
14
down-regulated)
participated
hallmark
pathways.
Genes
upregulated
cells
less
at
diagnosis
when
compared
normal
samples
but
their
higher
indicated
adverse
survival
outcomes.
Next,
these
used
for
CNC
construction
triad
FLT4:MIR503HG:miR-497/195/424
was
discovered.
The
levels
miRNAs
predicted
analysis
quantitative
RT-PCR
validate
down
regulation
miR-497/195/424
upregulation
targets,
FLT4
MIR503HG
cells.
Conclusions
show
total
RNA-seq
data
can
successfully
predict
achieve
drug
resistance.
Re-expression
such
as
tumor
diagnosis,
may
indicative
onset.
Finally,
arise
due
suppression
miR-424/497/195
leading
MIR503HG.
posit
suitable
target
could
developed
detection
strategy
cancer.
PeerJ,
Journal Year:
2024,
Volume and Issue:
12, P. e18733 - e18733
Published: Dec. 18, 2024
Among
women
with
cancer,
breast
cancer
has
surpassed
lung
to
become
the
most
prevalent
type
of
globally.
High-throughput
sequencing
tissues
from
many
patients
revealed
significant
variations
in
circRNA
expression
across
different
types
cancer.
Chemotherapy
is
currently
a
very
important
method
for
treating
cancer;
however,
as
number
chemotherapy
sessions
increases
and
considering
factors
such
patient’s
immune
response,
drug
resistance
challenging
issue
It
well
known
that
associated
multiple
factors,
mechanisms
involve
roles
circRNA.
This
review
consolidates
literature
past
5
years
addresses
shortcomings
broad
description
circRNA’s
role
resistance.
categorizes
describes
its
signaling
pathways
Oncology,
Journal Year:
2023,
Volume and Issue:
25(4), P. 255 - 261
Published: Jan. 1, 2023
Summary.
Hormone-dependent
malignant
neoplasms
are
the
most
common
form
of
breast
cancer
(BC)
worldwide.
The
high
heterogeneity
clinical
manifestations
and
response
to
treatment
indicates
need
search
for
prognostic
predictive
markers
predict
aggressiveness
course
hormone-dependent
BC
prescribe
individualized
tactics.
MicroRNAs
short
RNA
molecules
that
play
an
important
role
in
regulating
expression
many
genes.
This
is
due
fact
miRNAs
modulators
growth,
differentiation
metastasis
various
histogenesis,
including
BC.
can
be
used
disease
choose
optimal
tactics,
since
their
levels
determined
not
only
tumor
tissue
but
also
blood
serum.
systematization
generalization
results
our
own
research
data
from
literature
on
possibility
using
miRNA
as
perceptiveness
monitor
process
determine
sensitivity
tumors
neoadjuvant
hormonal
therapy.
